NCT02687906View on ClinicalTrials.gov

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Bacterial Infections
Interventions
DRUG

Vabomere

Vabomere (meropenem-vaborbactam) for IV injection

Trial Locations (9)

43606

Toledo Children's Hospital, Toledo

44106

Rainbow Babies and Childrens Hospital, Cleveland

60614

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

68114

University of Nebraska Medical Center, Omaha

72202

Arkansas Children's Hospital, Little Rock

90095

Ronald Reagan UCLA Medical Center, Los Angeles

92123

Rady Children's Hospital San Diego, San Diego

92868

Children's Hospital of Orange County, Orange

08901

Rutger's University, New Brunswick

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

INDUSTRY

NCT02687906 - Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections | Biotech Hunter | Biotech Hunter